If it weren’t for the recent passage of the Patient Protection and Affordable Care Act (PPACA), there would have been very little progress made toward reducing the overall number and the percentage of uninsured adults in the United States.

Efforts to expand children’s coverage is another matter.

Census Bureau statistics bear this out: The portion of children who lack coverage declined from 12.5 percent in 1999 to 9.9 percent in 2008. What caused this? Gains in Medicaid and the Children’s Health Insurance Program, with 1.7 million more children covered than a year earlier. Also, the number of uninsured children below the federal poverty level decreased in 2008 to 2.2 million — a 5.7 percentage point drop.

PPACA will affect children’s coverage in a number of ways. For example, beginning in 2014, the law makes Medicaid coverage mandatory for kids ages 6–19 in families between 100 percent and 133 percent of the federal poverty level. The Children’s Health Insurance Program (CHIP) will continue through 2019. States can expect a significant increase in the CHIP match rate, up to 100 percent of costs, in 2015. Current match rates range from 65 to 85 percent.

2010 federal poverty level guidelines
Percent poverty guidelines
Family size 100% 133% 200%
2 $14,570 $19,378 $29,140
3 $18,310 $24,352 $36,620
4 $22,050 $29,326 $44,100
Source: 2010 Federal Poverty Guidelines, U.S. Department of Health and Human Services

Private insurer coverage of children under PPACA

Plans will have to cover pre-existing conditions for currently insured children and not exclude children with pre-existing conditions from future coverage. The requirement becomes effective with the insurance plan years that begin after Sept. 23, 2010 (the year starts Jan. 1, 2011 for most people).

After September 23, 2010

  • Young adults can remain on their parents’ health plan until they turn 26.
  • Children under 19 with private insurance can no longer be denied coverage for pre-existing conditions.
  • Insurers may no longer impose lifetime caps or restrictive annual limits on coverage, and may not rescind coverage when a person becomes ill.
  • New plans must provide free preventive services to enrollees.

Source: Center for Children and Families, Georgetown University

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.